| Statins Reverse Doxorubicin Resistance in Mesothelioma Cells
NEW YORK JUL 12, 2006 (Reuters Health) - Statins reverse doxorubicin resistance in human malignant mesothelioma cells in culture, a finding that may lead to new clinical strategies to improve doxorubicin efficacy in this hard to treat cancer. "The mechanism of statin-mediated inhibition of small G-protein function is the molecular basis of the drug-elicited reversion of doxorubicin resistance in human malignant mesothelioma cells," Dr. Amalia Bosia from University of Torino, Italy told Reuters Health. Dr. Bosia and colleagues investigated the ability of statins to reverse resistance to doxorubicin in drug-resistant primary human malignant mesothelioma cells and the molecular mechanism behind the reversion, according to their report in the July 1st issue of the International Journal of Cancer.
Compensation speeded up for asbestos cancer claims
PEOPLE suffering from lung cancer after being exposed to asbestos will receive compensation more quickly under moves introduced by the government yesterday. John Hutton, the Work and Pensions Secretary, said the system would be speeded up to ensure people suffering from mesothelioma received their money before they died. He said interim measures to speed up the claims process would be put into action now.. About 1,800 people are currently diagnosed with mesothelioma each year, and as many as 2,400 people could die from it annually by 2013. But while the disease has a long latency period, people typically die within 12 to 18 months of having it diagnosed. Under the new measures insurance claims handlers will be told to give priority to mesothelioma claims.
Alfacell Corporation Announces Common Stock and Warrant Offering ...
BLOOMFIELD, N.J., July 20 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL - News) announced today that the Company has closed a private equity placement led by ProMed Management, Inc. and several other select institutional and individual investors to purchase 6,457,172 shares of its common stock at a price of $1.75 per share. Additionally, the Company issued to the investors two sets of Warrants as set forth and described below: The offering provided gross proceeds of approximately $11.3 million to Alfacell before deducting certain fees and expenses. The proceeds of the financing will be used for general corporate purposes and, most importantly, to support the Company's three-year strategic plan. Concurrent with the purchase agreement with the investors in the financing, the Company agreed to amend currently outstanding warrants to purchase 1,374,585 shares held by certain investors in the financing.
Asbestos settlement: after five years, Washington workers to vote ...
Thousands of asbestos victims will vote on an offer of compensation which will see them get 60% of what is due. The former Washington Chemical Company workers have fought a long battle for compensation after exposure to asbestos by the company. But people who were affected by living near the plant will only get 20% of their award if the offer is accepted. The award, if accepted, will utilise a £36m compensation cash pot, frozen for five years, which has finally been made available. Parent company Federal Mogul went into administration in 2001, freezing compensation payments. If the company hadn't gone into administration, sufferers would have got 100% compensation. This week claimants will receive a 500-page document from Federal Mogul administrators laying out terms of the latest offer and former workers, many of whom suffer from mesothelioma, will now vote on the settlement.
Alimta® or with Platinol® Benefits Patients with Recurrent Mesothelioma
According to results recently published in the Journal of Thoracic Oncology, treatment with the chemotherapy agent Alimta® (pemetrexed) with or without the chemotherapy agent Platinol® (cisplatin) provides benefit for patients with malignant mesothelioma who have received prior therapies. Malignant pleural mesothelioma is a rare cancer that develops in the tissue that covers the lungs and lines the interior of the chest. It is often caused by chronic exposure to asbestos. The majority of patients are not diagnosed until the disease has progressed to an advanced stage and treatment with surgery or radiation is not an option. Patients with this disease often experience symptoms, such as shortness of breath, cough, pain, fatigue, and an inability to eat, which lessen their quality of life.
|
